Description
Global Constrained Peptide Drugs Market Industry Overview
The global constrained peptide drugs market revenue has been forecasted from 2024 to 2040, following the earliest launch of the first constrained peptide drug in the market.
The market size is anticipated to be $0.06 billion in 2024 and is expected to reach $17.38 billion in 2040, growing at a CAGR of 38.94% during the forecast period 2025-2040.
Market Lifecycle Stage
The global constrained peptide drugs market is anticipated to witness tremendous growth during the forecast period 2025-2040, largely fuelled by the promise of a novel breakthrough constrained peptide pipeline, which is no longer restricted to receptor targets. Advancements in chemical technologies, the therapeutics’ success of commercialized synthetic peptides in recent years, and the affordable pricing being realized by these biomolecules in a wide range of diseases are some additional factors attributing to the projected growth in the forecast period.
Impact
The impact analysis for the factors that significantly affect the market, namely, drivers, restraints, and opportunities, has been provided on a short-term and long-term basis. The short-term assessment considers the period between 2020 and 2025, and the long-term assessment considers the period between 2026 and 2040. Key developments and strategies that have been undertaken by some of the key players in this market have been accounted for evaluation of the impact analysis. Further, these key developments have been assessed to understand the future scope of integrating advancing technologies to enable superior outcomes. Additionally, approvals and launches from companies and patent bodies have also been considered while evaluating the dynamics of the global constrained peptide drugs market.
Impact of COVID-19
In December 2019, Wuhan, a city in the Hubei region of China, was the site of the first detection of the COVID-19 outbreak. Following the classification of COVID-19 as novel pneumonia due to a cluster of unexplained pneumonia cases, efforts to pinpoint the culprit causing the outbreak and outline its genomic sequence got underway right once. The virus has already spread to every country on the globe, and researchers, governments, and business leaders are working to find answers to the crisis at a scale and speed that has never been seen. Testing for SARS-CoV-2 in the populace is one of the main steps that has been put into place globally, among many other measures used to stop the spread of the disease.
The global constrained peptide drugs market is a research-oriented market, having a majority of products in clinical trial stages. It primarily consists of clinical-stage biopharmaceutical companies and global biopharmaceutical companies such as Bicycle Therapeutics PLC, Protagonist Therapeutics, Inc., Aileron Therapeutics, Inc., Polyphor, and Santhera Pharmaceuticals Holding. Since most of the products are in the clinical phase of drug development, constrained peptide drug companies had a low impact on the COVID-19 pandemic.
Although clinical trials were brought to pause because of the lockdowns imposed by governments across the world, causing a delay in the clinical trial timeline, and volunteers and patients were also not able to participate in the clinical trials due to the lockdown; however, few companies took the opportunity of the pandemic and initiated the development of potential drugs against COVID-19. For instance, UCB Pharma participated in the COVID-19 Moonshot, an initiative to expedite the development of an anti-viral for COVID-19. The company’s Phase III investigational molecule Zilucoplan is being studied for acute respiratory distress syndrome associated with COVID-19. Another company, Polyphor Limited, is evaluating Balixafortide, a constrained peptide drug, against COVID-19 as it demonstrated strong efficacy in in-vitro models.
During the pre-COVID-19 period, the global constrained peptide drugs market observed 38 significant key developments. Out of the 38 key developments, the majority were funding activities, primarily focused on the development of novel antibiotics and support clinical trials of certain drugs in clinical phases. For example, in May 2019, Innosuisse awarded Polyphor Ltd. and the University of Zurich to escalate the development of novel antibiotics for treating infections caused by gram-negative bacteria. Furthermore, seven synergistic activities were undertaken in the global constrained peptide drugs market before COVID-19.
Market Segmentation:
Segmentation 1: by Peptide Type
• Disulfide-Rich Peptides (DRPs)
• Cyclic Peptides
Based on peptide type, the disulfide-rich peptides (DRPs) segment is anticipated to dominate the global constrained peptide drugs market in 2040 as the segment includes the pipeline-constrained peptide with either limited existing treatment options or no approved drugs for the disease.
Segmentation 2: by Region
• North America
• Europe
• Asia-Pacific
The North America region is anticipated to dominate the global constrained peptide drugs market (by region) during the forecast period 2025-2040. The reasons contributing to the high demand for constrained peptide drugs in North America are the increasing prevalence of target indications and the early launch of pipeline products in the U.S. and Canada.
Segmentation 3: by Potential Product
• BT5528
• Rusfertide (PTG-300)
• PN-943
• PN-235
• Zilucoplan (RA101495)
Segmentation 4: by Company
• Aileron Therapeutics, Inc.
• Bicycle Therapeutics plc
• Spexis AG
• Protagonist Therapeutics Inc.
• Santhera Pharmaceuticals
• Union Chimique Belge S.A. (UCB)
• Creative Peptides
• Biosynth (Pepscan)
• Pepticom Ltd.
• PeptiDream, Inc.
• Bio-Synthesis Inc
• CPC Scientific Inc.
• Circle Pharma
• Zealand Pharma
• Chugai Pharmaceutical Co., Ltd.
Based on the company, the global constrained peptide drugs market is dominated by 15 major companies.
Recent Developments in the Global Constrained Peptide Drugs Market
• In August 2021, Protagonist Therapeutics Inc. declared the resolution of its collaboration agreement with Zealand Pharma through the reduction of future milestone payments, sales milestones, and royalties owed to Zealand Pharma regarding Protagonist Therapeutics Inc.’s product candidate rusfertide under the terms of the 2012 collaboration agreement between the companies.
• In April 2021, Union Chimique Belge S.A. (UCB) anticipated the release of phase 3 key results for generalized myasthenia gravis (gMG) in the fourth quarter of 2021 and discontinued further development of zilucoplan for immune-mediated necrotizing myopathy (IMNM).
• In September 2021, Polyphor Limited and EnBiotix announced the successful closing of the purchase agreement for EnBiotix to acquire the inhaled antibiotic murepavadin.
• In November 2020, Pepscan Therapeutics B.V. was granted a license for the use of the proprietary CLIPS technology offered by Bicycle Therapeutics plc. The peptide-constraining technology would further help in the development of the company’s products named BT1718 and THR-149.
• In June 2020, Santhera Pharmaceuticals secured a financing commitment of up to $22.1 million from a fund managed by Highbridge Capital Management.
Demand – Drivers and Limitations
The following are the demand drivers for the global constrained peptide drugs market:
• Enhanced Binding Affinity and Cellular Uptake
• Development of Synthetic Constraining Method
• Limitations with Conventional Peptides
• Increasing Government and Private Funding
The market is expected to face some limitations due to the following challenges:
• Increased Competition from Biologics
• Risk of Immunogenic Effects and Unsatisfactory ADME Properties
How can this report add value to an organization?
Workflow/Innovation Strategy: The global constrained peptide drugs market has been segmented (by product) into five candidates, i.e., BT5528, Rusfertide (PTG-300), Zilucoplan (RA101495), PN-235, and PN-943. Over the past decade, peptide drug discovery and development has witnessed a renaissance and scientific thrust as the industry has come to acknowledge the capability of peptide therapeutics in addressing unmet medical needs and the potential of this class of molecules to become a significant accompaniment or even favored alternative treatment to biologics and small molecules.
Peptide therapeutics have demonstrated a novel and selective yet safe mode of action for a wide range of indications. The existing and future development of constrained peptide drugs will continue to burgeon upon the strengths of constrained peptides and innovative technologies employed in the discovery and development, including peptide drug conjugates, multifunctional peptides, and cell-penetrating peptides. Furthermore, limitations associated with presently available peptides have resulted in an urgent need for new design, administration, and synthesis in peptide therapeutics, thereby leading to advancements in the development of constrained peptides.
Growth/Marketing Strategy: Constrained peptides provide noteworthy advantages over linear peptides. An increase in interest in the field of constrained peptides due to the properties they offer led to advancements in peptide synthesis technologies. Companies such as PeptiDream Inc., Pepticom Ltd., Bicycle Therapeutics plc, and Polyphor Limited offer proprietary drug development and constrained peptide synthesis technologies. PeptiDream Inc.’s proprietary Peptide Discovery Platform System (PDPS) technology is used to synthesize synthetic non-native peptide libraries expeditiously, which helps in identifying peptides that can be used as potential drugs for a disease.
Competitive Strategy: Key players in the global constrained peptide drugs market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global constrained peptide drugs market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Table of Contents
1 Definition
1.1 Inclusion and Exclusion Criteria
2 Research Scope
2.1 Target Audience
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Constrained Peptides: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 Markets Overview
4.1 Introduction
4.1.1 Structure and Design of Constrained Peptides
4.1.2 Types of Constrained Peptides
4.2 Evolution of Constrained Peptides
4.3 Development of Constrained Peptides as Drugs
4.4 Potential Therapy Areas
4.5 Value Chain-Key Stakeholders
4.6 Key Industry Trends (by Region)
4.7 Key Industry Trends by Route of Administration
4.8 Key Industry Trends-Technological Advancements
4.9 Current Market Size and Growth Potential, $Billion, 2024-2040
4.1 COVID-19 Impact on Global Constrained Peptides Drugs Market
4.10.1 Impact on Constrained Peptide Drugs Companies
4.10.2 Clinical Trial Disruptions and Resumptions
5 Characteristics of Conformationally Constrained Peptides
5.1 Properties of Conformationally Constrained Peptides
5.2 Synthesis of Constrained Peptides
5.2.1 Chemical Peptide Ligation and Bridging
5.2.2 Chemical Linkage of Peptides onto Scaffolds (CLIPS)
5.2.3 Peptide Stapling
5.2.4 Peptide Discovery Platform System (PDPS)
5.2.5 Liquid Phase Peptide Synthesis (LPPS)
5.2.6 Solid Phase Peptide Synthesis (SPPS)
5.3 Advances in Peptide Technology
5.3.1 Synthesis of Peptides Using Microflow Technology
5.3.2 Microwave-Assisted Solid-Phase Peptide Synthesis
5.4 Peptide Display and Selection System
6 Industry Insights
6.1 Overview
6.2 Challenges in Constrained Peptides Regulatory Approval Pathway
6.3 Regulatory Scenario of Constrained Peptides
6.4 Legal Requirements and Frameworks in the U.S.
6.4.1 Clinical Trial Authorization
6.4.2 Marketing Authorization
6.4.3 U.S. FDA Guidelines for NDA Submission
6.4.4 Post-Authorization Regulations
6.5 Legal Requirements and Frameworks in Europe
6.5.1 EMA Drug License Application Process
6.5.2 Centralized Procedure
6.5.3 Decentralized Procedure
6.5.4 Mutual-Recognition Procedure
6.5.5 National Procedure
6.6 Legal Requirements and Frameworks in Asia-Pacific
6.6.1 Legal Requirements and Frameworks in Japan
6.7 Reimbursement Scenario
6.7.1 Reimbursement Scenario for Autoimmune Diseases
6.7.2 Reimbursement Scenario for Cancer
6.7.3 Reimbursement Scenario for Rare Diseases
7 Market Dynamics
7.1 Impact Analysis
7.2 Market Drivers
7.2.1 Enhanced Binding Affinity and Cellular Uptake
7.2.2 Development of Synthetic Constraining Methods
7.2.3 Limitations with Conventional Peptides
7.2.4 Increasing Government and Private Funding
7.2.4.1 Funding by Private Companies
7.2.4.2 Funding by Public Companies
7.2.4.3 Funding by Government Institutions
7.3 Market Restraints
7.3.1 Increased Competition from Biologics
7.3.2 Risk of Immunogenic Effects and Unsatisfactory ADME Properties
7.4 Market Opportunities
7.4.1 Role of Constrained Peptides in Drug Discovery
7.4.2 Various Applications in CNS Disease Studies and Anti-Cancer Therapy
8 Competitive Landscape
8.1 Competitive Landscape Overview
8.1.1 Key Developments
8.1.2 Regulatory and Legal Activities
8.1.3 Mergers and Acquisitions
8.1.4 Synergistic Activities
8.1.5 Funding Activities
8.1.6 Clinical Developments
9 Global Constrained Peptides Drugs Market (by Pipeline), $Million, 2024-2040
9.1 Constrained Peptide Drugs Clinical Trial Design
9.1.1 Potential Phase II Drugs
9.1.2 BT5528
9.1.2.1 Product Profile
9.1.2.2 Study Design (Phase I/II)
9.1.2.3 Efficacy, Safety, and Tolerability Data (Phase I)
9.1.2.4 BT5528 Preclinical Studies
9.1.3 PN-943
9.1.3.1 Product Profile
9.1.3.2 Study Design (Phase II)
9.1.3.3 Efficacy, Safety, and Tolerability Data (Phase II)
9.1.4 PN-235
9.1.4.1 Product Profile
9.1.4.2 Study Design (Phase IIb)
9.1.4.3 Efficacy, Safety, and Tolerability Data (Phase IIb)
9.1.5 Rusfertide (PTG-300)
9.1.5.1 Product Profile
9.1.5.2 Study Design (Phase II)
9.1.5.3 Efficacy, Safety, and Tolerability Data (Phase IIa)
9.1.6 Potential Phase III drugs
9.1.7 Zilucoplan (RA101495)
9.1.7.1 Product Profile
9.1.7.2 Study Design (Phase III)
9.1.7.3 Efficacy, Safety, and Tolerability Data (Phase III)
9.1.7.4 Zilucoplan Pharmacokinetics and Pharmacodynamics Profile (Phase I)
9.1.8 Rusfertide (PTG-300)
9.1.8.1 Product Profile
9.1.8.2 Study Design (Phase III)
9.1.8.3 Efficacy, Safety, and Tolerability Data (Phase II)
9.2 Global Constrained Peptides Drugs Market Pipeline Analysis, $Million, 2024-2040
9.2.1 Pre-Clinical
9.2.1.1 Probability of Success
9.2.2 Clinical (Phase I-III)
9.2.2.1 Probability of Success
9.2.2.2 Cost of API Manufacturing (CDMOs)
10 Global Constrained Peptides Drugs Market (by Peptide Type), $Million, 2024-2040
10.1 Global Constrained Peptide Drugs Market (by Peptide Type), $Billion, 2024-2040
10.1.1 Overview
10.1.2 Cyclic Peptides
10.1.3 Disulfide-Rich Peptides (DRPs)
11 Global Constrained Peptides Drugs Market (by Potential Products), $Million, 2024-2040
11.1 Overview
11.1.1 BT5528
11.1.1.1 API Manufacturing (Outsource)
11.1.1.2 API Demand Forecast 2024-2040
11.1.1.3 Cost of Outsourcing
11.1.2 Zilucoplan (RA101495)
11.1.2.1 API Manufacturing (In-House)
11.1.2.2 API Demand Forecast 2024-2040
11.1.3 Rusfertide (PTG-300)
11.1.3.1 API Manufacturing (Outsource)
11.1.3.2 API Demand Forecast 2024-2040
11.1.3.3 Cost of Outsourcing
11.1.4 PN-943
11.1.4.1 API Manufacturing (Outsource)
11.1.4.2 API Demand Forecast 2024-2040
11.1.4.3 Cost of Outsourcing
11.1.5 PN-235
11.1.5.1 API Manufacturing (Outsource)
11.1.5.2 API Demand Forecast 2024-2040
11.1.5.3 Cost of Outsourcing
12 Global Constrained Peptides Drugs Market (by Country), $Million, 2024-2040
12.1 Global Constrained Peptide Drugs Market (by Country), $Billion, 2024-2031
12.1.1 North America
12.1.1.1 U.S.
12.1.1.2 Canada
12.1.2 Europe
12.1.2.1 U.K.
12.1.2.2 Germany
12.1.2.3 France
12.1.2.4 Italy
12.1.2.5 Spain
12.1.3 Asia-Pacific
12.1.3.1 Japan
13 Company Profiles
13.1 Overview
13.2 Aileron Therapeutics, Inc.
13.2.1 Company Overview
13.2.2 Role of Aileron Therapeutics, Inc. in the Global Constrained Peptide Drugs Market
13.2.3 Current Status and Policies for Investigational Drugs
13.2.4 Key Competitors of the Company
13.2.5 Financials
13.2.6 Key Insights about the Financial Health of the Company
13.2.7 Corporate Strategies
13.2.7.1 Synergistic Activities
13.2.7.2 Funding Activity
13.2.8 Business Strategies
13.2.8.1 Clinical Development
13.2.9 Analyst Perspective
13.3 Bicycle Therapeutics plc
13.3.1 Company Overview
13.3.2 Role of Bicycle Therapeutics plc in the Global Constrained Peptide Drugs Market
13.3.1 Current Status and Policies for Investigational Drugs
13.3.2 Key Competitors of the Company
13.3.3 Financials
13.3.4 Key Insights about the Financial Health of the Company
13.3.5 Corporate Strategies
13.3.5.1 Synergistic Activities
13.3.5.2 Funding
13.3.6 Business Strategies
13.3.6.1 Clinical Developments
13.3.6.2 Regulatory and Legal
13.3.7 Analyst Perspective
13.4 Spexis AG
13.4.1 Company Overview
13.4.2 Role of Spexis AG in the Global Constrained Peptide Drugs Market
13.4.3 Current Status and Policies for Investigational Drugs
13.4.4 Key Competitors of the Company
13.4.5 Financials
13.4.6 Key Insights about the Financial Health of the Company
13.4.7 Corporate Strategies
13.4.7.1 Funding
13.4.7.2 Mergers and Acquisitions
13.4.7.3 Synergistic activities
13.4.8 Business Strategies
13.4.8.1 Regulatory and Legal
13.4.9 Analyst Perspective
13.5 Protagonist Therapeutics Inc.
13.5.1 Company Overview
13.5.2 Role of Protagonist Therapeutics Inc. in the Global Constrained Peptide Drugs Market
13.5.3 Current Status and Policies for Investigational Drugs
13.5.4 Key Competitors of the Company
13.5.5 Financials
13.5.6 Key Insights about the Financial Health of the Company
13.5.7 Corporate Strategies
13.5.7.1 Funding
13.5.7.2 Synergistic Activities
13.5.8 Business Strategies
13.5.8.1 Clinical Developments
13.5.8.2 Regulatory and legal
13.5.9 Analyst Perspective
13.6 Santhera Pharmaceuticals
13.6.1 Company Overview
13.6.2 Role of Santhera Pharmaceuticals in the Global Constrained Peptide Drugs Market
13.6.3 Current Status and Policies for Investigational Drugs
13.6.4 Key Competitors of the Company
13.6.5 Financials
13.6.6 Corporate Strategies
13.6.6.1 Funding
13.6.7 Business Strategies
13.6.7.1 Clinical Developments
13.6.8 Analyst Perspective
13.7 Union Chimique Belge S.A. (UCB)
13.7.1 Company Overview
13.7.2 Role of Union Chimique Belge S.A. (UCB) in the Global Constrained Peptide Drugs Market
13.7.3 Current Status and Policies for Investigational Drugs
13.7.4 Key Competitors of the Company
13.7.5 Financials
13.7.6 Key Insights about the Financial Health of the Company
13.7.7 Corporate Strategies
13.7.7.1 Mergers and Acquisitions
13.7.8 Business Strategies
13.7.8.1 Clinical Developments
13.7.8.2 Regulatory and legal
13.7.9 Analyst Perspective
13.8 Creative Peptides
13.8.1 Company Overview
13.8.2 Role of Creative Peptides in the Global Constrained Peptide Drugs Market
13.8.3 Key Competitors of the Company
13.8.4 Analyst Perspective
13.9 Biosynth (Pepscan)
13.9.1 Company Overview
13.9.2 Role of Biosynth (Pepscan) in the Global Constrained Peptide Drugs Market
13.9.3 Key Competitors of the Company
13.9.4 Corporate Strategies
13.9.4.1 License
13.9.5 Business Strategies
13.9.5.1 Product Launch
13.9.6 Analyst Perspective
13.1 Pepticom Ltd.
13.10.1 Company Overview
13.10.2 Role of Pepticom Ltd. in the Global Constrained Peptide Drugs Market
13.10.3 Analyst Perspective
13.11 PeptiDream, Inc.
13.11.1 Company Overview
13.11.2 Role of PeptiDream, Inc. in the Global Constrained Peptide Drugs Market
13.11.3 Key Competitors of the Company
13.11.4 Financials
13.11.5 Corporate Strategies
13.11.5.1 Synergistic Activities
13.11.6 Analyst Perspective
13.12 Bio-Synthesis Inc
13.12.1 Company Overview
13.12.2 Role of Bio-Synthesis Inc in the Global Constrained Peptide Drugs Market
13.12.3 Key Competitors of the Company
13.12.4 Analyst Perspective
13.13 CPC Scientific Inc.
13.13.1 Company Overview
13.13.2 Role of CPC Scientific Inc. in the Global Constrained Peptide Drugs Market
13.13.3 Key Competitors of the Company
13.13.4 Analyst Perspective
13.14 Emerging Companies
13.14.1 Circle Pharma
13.14.1.1 Platform
13.14.1.2 Pipeline Products
13.14.2 Zealand Pharma
13.14.2.1 ZP10000 (Preclinical)
13.14.2.1.1 Product Profile
13.14.3 Chugai Pharmaceutical Co., Ltd.
13.14.3.1 Mid-Size Molecule Technology
List of Figures
Figure 1: Total Number of Drugs Approved by the U.S. FDA, 2016-2021
Figure 2: Global Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 3: Global Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 4: Global Constrained Peptide Drugs: Impact Analysis
Figure 5: Revenue Contribution of Different Segments, 2024 and 2031
Figure 6: Global Constrained Peptide Drugs Market (by Potential Product), $Billion, 2024-2040
Figure 7: Global Constrained Peptide Drugs Market (by Region), $Billion, 2024-2040
Figure 8: Global Constrained Peptide Drugs Market Segmentation
Figure 9: Global Constrained Peptide Drugs Methodology
Figure 10: Primary Research Methodology
Figure 11: Epidemiology-Based Approach
Figure 12: Inducing Conformational Effects
Figure 13: Two Main Types of Constraints
Figure 14: Methodology for Restricting Conformation in Peptides
Figure 15: Types of Constrained Peptides
Figure 16: Key Milestones in the Evolution of Constrained Peptides
Figure 17: Major Factors Affecting Constrained Peptide Development
Figure 18: Value Chain Analysis- Key Stakeholders
Figure 19: Global Constrained Peptide Drugs Market (by Region), $Billion, 2024-2031
Figure 20: Global Constrained Peptide Drugs Market (by Region), $Billion, 2032-2040
Figure 21: Global Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 22: Global Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 23: Synthesis of Constrained Peptides using Chemical Peptide Ligation and Bridging
Figure 24: Constrained Peptide Synthesis using CLIPS Technology
Figure 25: Constrained Peptides Synthesis using Peptide Stapling
Figure 26: Peptide Discovery Platform System (PDPS) Technology
Figure 27: Synthesis of Peptides Using Liquid Phase Peptide Synthesis
Figure 28: Synthesis of Peptides Using Solid Phase Peptide Synthesis
Figure 29: Companies and Their Proprietary Technologies
Figure 30: Features of Microflow Reaction for Peptide Synthesis
Figure 31: Advantages of Microwave-Assisted Solid-Phase Peptide Synthesis
Figure 32: Phage Display Technology
Figure 33: Clinical Trial Authorization for Constrained Peptides in the U.S.
Figure 34: Steps for Obtaining Marketing Authorization
Figure 35: U.S. FDA Review Timeline
Figure 36: EMA Review Timeline
Figure 37: Factors Affecting Constrained Peptide Cellular Penetration
Figure 38: Key Innovative Modern Technologies and Constraining Methods
Figure 39: Properties of Traditional Peptides Vs. Constrained Peptides
Figure 40: Share of Key Developments and Strategies, January 2018 to January 2023
Figure 41: Share of Regulatory and Legal Activities (by Company), January 2018 to January 2023
Figure 42: Share of Mergers and Acquisitions (by Company), January 2018 to January 2023
Figure 43: Share of Synergistic Activities (by Company), January 2018 to January 2023
Figure 44: Share of Funding Activities (by Company), January 2018 to January 2023
Figure 45: Illustration of BT5528
Figure 46: Tumors with EphA2 Over-Expression
Figure 47: BT5528 Phase I/II Clinical Trial Design for Solid Tumors
Figure 48: BT5528 Preclinical Studies Framework
Figure 49: PN-943 Phase II IDEAL Study Intervention Model Design
Figure 50: PN-943 Phase II Clinical Trial Design for Moderate-to-Severe Ulcerative Colitis (UC)
Figure 51: Results from PN-943 Phase I Clinical Trial
Figure 52: PN-235 Phase IIb Clinical Trial Design for Moderate-to-Severe Plaque Psoriasis
Figure 53: Rusfertide (PTG-300) Mechanism of Action
Figure 54: Rusfertide (PTG-300) Phase III clinical Design for Hereditary Hemochromatosis
Figure 55: Zilucoplan (RA101495) Mechanism of Action
Figure 56: Zilucoplan Phase III Clinical Trial Design for Generalized Myasthenia Gravis
Figure 57: Zilucoplan Phase III Clinical Trial Design for Generalized Myasthenia Gravis
Figure 58: Zilucoplan Safety and Efficacy Tolerability Profile
Figure 59: Zilucoplan PK/PD Profile Results
Figure 60: Rusfertide (PTG-300) Mechanism of Action
Figure 61: Limited Current Treatment Options in Polycythemia Vera
Figure 62: Rusfertide (PTG-300) Phase III Clinical Design for Polycythemia Vera
Figure 63: Clinical Proof-of-Concept Study Intervention Model Design
Figure 64: Cost of API Manufacturing (by Product), $Million, 2024-2031
Figure 65: Cost of API Manufacturing (by Product), $Million, 2032-2040
Figure 66: Revenue Contribution of Different Segments, 2024 and 2031
Figure 67: Global Constrained Peptide Drugs Market (Cyclic Peptides), $Billion, 2024-2031
Figure 68: Global Constrained Peptide Drugs Market (Cyclic Peptides), $Billion, 2032-2040
Figure 69: Global Constrained Peptide Drugs Market (Disulfide-Rich Peptides), $Billion, 2024-2031
Figure 70: Global Constrained Peptide Drugs Market (Disulfide-Rich Peptides), $Billion, 2032-2040
Figure 71: Global Constrained Peptide Drugs Market (by Product), $Billion, 2024-2040
Figure 72: Global Revenue for BT5528, $Billion, 2024-2031
Figure 73: Global Revenue for BT5528, $Billion, 2032-2040
Figure 74: BT5528.: API Manufacturing
Figure 75: BT5528: API Demand Forecast, by Volume, Kilogram, 2024-2031
Figure 76: BT5528: API Demand Forecast, by Volume, Kilogram, 2032-2040
Figure 77: Global Revenue for Zilucoplan (RA101495), $Billion, 2024-2031
Figure 78: Global Revenue for Zilucoplan (RA101495), $Billion, 2032-2040
Figure 79: Zilucoplan (RA101495): API Manufacturing
Figure 80: Zilucoplan (RA101495): API Demand Forecast, by Volume, Kilogram, 2024-2031
Figure 81: Zilucoplan (RA101495): API Demand Forecast, by Volume, Kilogram, 2032-2040
Figure 82: Global Revenue for Rusfertide (PTG-300), $Billion, 2024-2031
Figure 83: Global Revenue for Rusfertide (PTG-300), $Billion, 2032-2040
Figure 84: Rusfertide (PTG-300).: API Manufacturing
Figure 85: Rusfertide (PTG-300): API Demand Forecast, by Volume, Kilogram, 2024-2031
Figure 86: Rusfertide (PTG-300): API Demand Forecast, by Volume, Kilogram, 2032-2040
Figure 87: Global Revenue for PN-943, $Billion, 2024-2031
Figure 88: Global Revenue for PN-943, $Billion, 2032-2040
Figure 89: PN-943.: API Manufacturing
Figure 90: PN-943: API Demand Forecast, by Volume, Kilogram, 2024-2031
Figure 91: PN-943: API Demand Forecast, by Volume, Kilogram, 2032-2040
Figure 92: Global Revenue for PN-235, $Billion, 2024-2031
Figure 93: Global Revenue for PN-235, $Billion, 2032-2040
Figure 94: PN-325.: API Manufacturing
Figure 95: PN-235: API Demand Forecast, by Volume, Kilogram, 2024-2031
Figure 96: PN-235: API Demand Forecast, by Volume, Kilogram, 2032-2040
Figure 97: Global Constrained Peptide Drugs Market (by Region)
Figure 98: Global Constrained Peptide Drugs Market (by Region), $Billion, 2024-2040
Figure 99: North America Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 100: North America Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 101: North America: Market Dynamics
Figure 102: North America Constrained Peptide Drugs Market (by Country), $Billion, 2024 and 2040
Figure 103: U.S. Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 104: U.S. Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 105: Canada Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 106: Canada Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 107: Europe Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 108: Europe Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 109: Europe: Market Dynamics
Figure 110: Europe Constrained Peptide Drugs Market (by Country), $Billion, 2025 and 2040
Figure 111: U.K. Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 112: U.K. Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 113: Germany Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 114: Germany Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 115: France Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 116: France Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 117: Italy Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 118: Italy Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 119: Spain Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 120: Spain Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 121: Japan Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 122: Japan Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 123: Total Number of Companies Profiled
Figure 124: Aileron Therapeutics, Inc.: Product Portfolio
Figure 125: Aileron Therapeutics, Inc.: Overall Financials, $Million, 2019-2021
Figure 126: Aileron Therapeutics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 127: Bicycle Therapeutics plc: Product Portfolio
Figure 128: Bicycle Therapeutics plc: Overall Financials, $Million, 2019-2021
Figure 129: Bicycle Therapeutics plc: Revenue (by Region), $Million, 2019-2021
Figure 130: Bicycle Therapeutics plc: R&D Expenditure, $Million, 2019-2021
Figure 131: Spexis AG: Product Portfolio
Figure 132: Spexis AG: Overall Financials, $Million, 2019-2021
Figure 133: Spexis AG: R&D Expenditure, $Million, 2019-2021
Figure 134: Protagonist Therapeutics Inc.: Product Portfolio
Figure 135: Protagonist Therapeutics Inc.: Overall Financials, $Million, 2019-2021
Figure 136: Protagonist Therapeutics Inc.: R&D Expenditure, $Million, 2019-2021
Figure 137: Santhera Pharmaceuticals: Product Portfolio
Figure 138: Santhera Pharmaceuticals: Overall Financials, $Million, 2019-2021
Figure 139: Union Chimique Belge S.A. (UCB): Product Portfolio
Figure 140: Union Chimique Belge S.A. (UCB): Overall Financials, $Million, 2019-2021
Figure 141: Union Chimique Belge S.A. (UCB): R&D Expenditure, $Million, 2019-2021
Figure 142: Creative Peptides: Product Portfolio
Figure 143: Biosynth (Pepscan): Product Portfolio
Figure 144: Pepticom Ltd.: Product Portfolio
Figure 145: PeptiDream, Inc.: Product Portfolio
Figure 146: PeptiDream, Inc.: Overall Financials, $Million, 2019-2021
Figure 147: Bio-Synthesis Inc Product Portfolio
Figure 148: CPC Scientific Inc.: Product Portfolio
List of Tables
Table 1: Potential Indications of Constrained Peptide Drugs
Table 2: Potential Therapy Areas of Constrained Peptide Drugs
Table 3: Route of Administration of Constrained Peptide Drugs
Table 4: Impact of COVID-19 on Constrained Peptide Drug Companies
Table 5: Properties of Conformationally Constrained Peptides
Table 6: Display and Selection System Employed by Companies
Table 7: Regulatory Scenario of Constrained Peptides
Table 8: Autoimmune Diseases Reimbursement Scenario
Table 9: Cancer Reimbursement Scenario
Table 10: Funding by Private Companies
Table 11: Rusfertide Phase II Baseline Characteristics Results
Table 12: Zilucoplan Phase III Baseline Characteristics Results
Table 13: Likeliness Scale for Probability of Success (Pre-Clinical)
Table 14: Likeliness Scale for Probability of Success (Pre-Clinical)
Table 15: Circle Drugs Pipeline”
